Outcome of children with refractory anaemia with excess of blast (RAEB) and RAEB in transformation (RAEB-T) in the Japanese MDS99 study

Br J Haematol. 2012 Sep;158(5):657-61. doi: 10.1111/j.1365-2141.2012.09210.x. Epub 2012 Jun 26.

Abstract

We report the outcome of 16 children with refractory anaemia with excess of blasts (RAEB; n = 4) and RAEB in transformation (RAEB-T; n = 12) following induction therapy with etoposide, cytarabine and mitoxantrone (ECM) prior to haematopoietic stem cell transplantation (HSCT). The median observation period was 77 months (range 5-123). Complete remission rate was 81% following induction; no toxic deaths occurred. Eight-year event-free survival and overall survival was 50% and 56%, respectively. None of the three patients with a complex karyotype survived, suggesting karyotype is a crucial prognostic factor for survival. This study indicates the safety and high remission rate of ECM and high survival rates after HSCT for paediatric RAEB and RAEB-T.

MeSH terms

  • Anemia, Refractory, with Excess of Blasts / pathology
  • Anemia, Refractory, with Excess of Blasts / therapy*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cell Transformation, Neoplastic / pathology
  • Child
  • Cytarabine / administration & dosage
  • Etoposide / administration & dosage
  • Hematopoietic Stem Cell Mobilization / methods
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Kaplan-Meier Estimate
  • Mitoxantrone / administration & dosage
  • Remission Induction / methods
  • Treatment Outcome

Substances

  • Cytarabine
  • Etoposide
  • Mitoxantrone